Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy plus iparomlimab and tuvonralimab for locally advanced cervical cancer
ChiCTR2500100876Phase 4Recruiting
- Sponsor
- PLA General Hospital Seventh Medical Center
- Start
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of iparomlimab, tuvonralimab, paclitaxel and cisplatin in Cervical Cancer (CC) (2 arms), sponsored by PLA General Hospital Seventh Medical Center. Primary endpoint: Objective response rate. Started Apr 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500100876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100876.